- Stocks
- Healthcare
- NASDAQ: RGEN

Price (delayed)

$199.73

Market cap

$11.15B

P/E Ratio

96.02

Dividend/share

N/A

EPS

$2.08

Enterprise value

$10.94B

Repligen is an American company devoted to the development and production of materials used in the manufacture of biological drugs. The company is based in Waltham, Massachusetts, and incorporated in

RGEN's quick ratio is up by 21% year-on-year and by 4.6% since the previous quarter

Repligen's equity has increased by 8% YoY

The stock's P/E is 60% above its last 4 quarters average of 59.9 but 21% below its 5-year quarterly average of 122.0

RGEN's gross profit is down by 32% YoY and by 20% QoQ

RGEN's EPS is down by 31% year-on-year and by 16% since the previous quarter

What are the main financial stats of RGEN

Market
Valuations
Earnings

Shares outstanding

55.83M

Market cap

$11.15B

Enterprise value

$10.94B

Price to earnings (P/E)

96.02

Price to book (P/B)

5.6

Price to sales (P/S)

16.63

EV/EBIT

86.17

EV/EBITDA

56.9

EV/Sales

16.33

Revenue

$669.78M

EBIT

$126.96M

EBITDA

$192.28M

Free cash flow

$97.48M

Per share
Balance sheet
Liquidity

EPS

$2.08

Free cash flow per share

$1.75

Book value per share

$35.67

Revenue per share

$12.01

TBVPS

$23.33

Total assets

$2.51B

Total liabilities

$525.57M

Debt

$419.89M

Equity

$1.99B

Working capital

$615.09M

Debt to equity

0.21

Current ratio

2.69

Quick ratio

2.03

Net debt/EBITDA

-1.1

Margins
Efficiency
Dividend

EBITDA margin

28.7%

Gross margin

46.8%

Net margin

17.3%

Operating margin

15.6%

Return on assets

4.6%

Return on equity

5.9%

Return on invested capital

16.2%

Return on capital employed

5.9%

Return on sales

19%

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

How has the Repligen stock price performed over time

Intraday

-4.17%

1 week

0.64%

1 month

12.2%

1 year

5.12%

YTD

11.08%

QTD

11.08%

How have Repligen's revenue and profit performed over time

Revenue

$669.78M

Gross profit

$313.3M

Operating income

$104.3M

Net income

$115.79M

Gross margin

46.8%

Net margin

17.3%

The operating income has plunged by 51% YoY and by 31% from the previous quarter

The operating margin has contracted by 41% YoY and by 25% from the previous quarter

RGEN's gross profit is down by 32% YoY and by 20% QoQ

The company's net income fell by 30% YoY and by 16% QoQ

What is Repligen's growth rate over time

What is Repligen stock price valuation

P/E

96.02

P/B

5.6

P/S

16.63

EV/EBIT

86.17

EV/EBITDA

56.9

EV/Sales

16.33

The stock's P/E is 60% above its last 4 quarters average of 59.9 but 21% below its 5-year quarterly average of 122.0

RGEN's EPS is down by 31% year-on-year and by 16% since the previous quarter

The P/B is 22% more than the last 4 quarters average of 4.6

Repligen's equity has increased by 8% YoY

RGEN's P/S is 40% above its last 4 quarters average of 11.9 but 5% below its 5-year quarterly average of 17.5

The revenue has contracted by 16% YoY and by 8% from the previous quarter

How efficient is Repligen business performance

The ROIC has plunged by 51% YoY and by 23% from the previous quarter

The return on equity has declined by 37% year-on-year and by 18% since the previous quarter

RGEN's ROA is down by 33% year-on-year and by 16% since the previous quarter

RGEN's return on sales is down by 26% year-on-year and by 15% since the previous quarter

What is RGEN's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for RGEN.

How did Repligen financials performed over time

RGEN's quick ratio is up by 21% year-on-year and by 4.6% since the previous quarter

Repligen's current ratio has increased by 16% YoY

The debt is 79% less than the equity

Repligen's debt to equity has decreased by 9% YoY

Repligen's equity has increased by 8% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.